Fragile X Syndrome (FXS) Treatment Global Market Report 2025
상품코드:1760534
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
취약 X 증후군 FXS 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 7.9%의 CAGR로 28억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 표적치료에 대한 수요 증가, 유전자 치료에 대한 관심 증가, 희귀 유전성 질환에 대한 인식 증가, 원격진료의 도입 확대, 희귀 질환 치료에 대한 보험 적용 확대 등에 기인하는 것으로 분석됩니다. 이 기간 동안 주요 동향으로는 유전자 검사 기술 발전, 유전자 편집 치료의 발전, 연구개발 투자 증가, 맞춤형 치료법의 혁신, 행동치료 접근법의 개선 등을 꼽을 수 있습니다.
희귀질환에 대한 정부의 노력과 재정적 지원은 가까운 미래에 취약X증후군(FXS) 치료제 시장의 성장을 견인할 것으로 예상됩니다. 희귀질환은 인구의 극히 일부가 앓고 있는 질환으로, 만성적이고 진행성이며 생명을 위협할 수 있는 경우가 많습니다. 희귀질환의 발견이 증가한 배경에는 유전자 검사, 영상 진단, 데이터 분석의 진단 능력 향상으로 이전에는 발견되지 않았거나 오진되었던 질환의 진단 정확도가 크게 향상되었기 때문입니다. 취약 X 증후군(FXS) 치료는 전문적인 치료와 조기 개입의 필요성을 강조함으로써 정부의 재정 지원의 중요성을 강조하고 있습니다. 예를 들어, 2024년 2월 영국 의회 하원 도서관은 영국 전역에 11개의 연구 노드와 중앙 조정 허브를 갖춘 국가 희귀질환 연구 플랫폼을 구축하기 위해 정부가 1,400만 파운드(1,730만 달러)를 지원할 것이라고 보고했습니다. 따라서 희귀질환에 대한 정부의 투자는 FXS 치료 시장의 성장을 가속화하고 있습니다.
취약 X 증후군(FXS) 치료 시장의 주요 기업들은 근본적인 신경 기능 장애를 해결하고 치료 결과를 개선하기 위해 칼슘 활성화 칼륨(BK) 채널 활성화제와 같은 혁신적인 치료법 개발에 우선순위를 두고 있으며, BK 채널 활성화제는 세포의 흥분성과 신경 전달 물질의 방출을 조절하고 칼륨 채널의 기능을 향상시킵니다. 예를 들어, 2025년 1월 미국 생명공학 기업 스피노제닉스는 미국 식품의약국(FDA)으로부터 FXS 치료용 BK채널 활성화제 SPG601에 대해 패스트트랙 지정을 받았습니다. 이번 지정으로 임상 개발 및 규제 당국의 승인을 앞당겨 시냅스 기능 장애를 해결하기 위해 고안된 이 새로운 치료 옵션이 환자들에게 보다 쉽게 다가갈 수 있게 됐습니다. 또한 효과적인 FXS 치료에 대한 시급한 필요성과 주요 신경학적 메커니즘을 표적으로 삼아 인지 및 행동 증상을 완화할 수 있는 SPG601의 잠재력을 반영하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 취약 X 증후군(FXS) 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 취약 X 증후군(FXS) 치료 시장 : 성장률 분석
세계의 취약 X 증후군(FXS) 치료 시장 실적 : 규모와 성장, 2019-2024년
세계의 취약 X 증후군(FXS) 치료 시장 예측 : 규모와 성장, , 2024-2029년, 2034년
세계의 취약 X 증후군(FXS) 치료 전체 시장(TAM)
제6장 시장 세분화
세계의 취약 X 증후군(FXS) 치료 시장 : 치료 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
약물 치료
심리요법
교육과 훈련
세계의 취약 X 증후군(FXS) 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
주사제
국소
세계의 취약 X 증후군(FXS) 치료 시장 : 관련 질환별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
취약 X 증후군
취약 X 증후군 1형(FMR1) 관련 원발성 난소 기능 부전
취약 X-연관 취약 E(XE) 증후군
렌페닝 증후군
기타 관련 질환
세계의 취약 X 증후군(FXS) 치료 시장 : 환자 연령층별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
아동
성인
노인
세계의 취약 X 증후군(FXS) 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원
전문 클리닉
기타 최종사용자
세계의 취약 X 증후군(FXS) 치료 시장, 약물 치료 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
항우울제
항정신병제
각성제
항경련제
항불안제
mGluR5 길항제(대사형 글루탐산 수용체 5 길항제)
GABA 작용제(γ-아미노 부티르산 작용제)
세계의 취약 X 증후군(FXS) 치료 시장, 심리요법 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
인지 행동 치료(CBT)
가족 요법
소셜 스킬 트레이닝
작업치료
언어치료
응용 행동 분석(ABA)
세계의 취약 X 증후군(FXS) 치료 시장, 교육과 훈련 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
특별 교육 프로그램
개별 교육 프로그램(IEP)
부모 트레이닝과 서포트
행동 개입 계획
스킬 구축 워크숍
포용적인 교실 전략
제7장 지역별·국가별 분석
세계의 취약 X 증후군(FXS) 치료 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 취약 X 증후군(FXS) 치료 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
취약 X 증후군(FXS) 치료 시장 : 경쟁 구도
취약 X 증후군(FXS) 치료 시장 : 기업 개요
F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
Shionogi & Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
Marinus Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
Healx Ltd Overview, Products and Services, Strategy and Financial Analysis
Neuren Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Vincerx Pharma Inc.
Fulcrum Therapeutics Inc.
Neuronascent Inc.
Autifony Therapeutics Limited
Quadrant Biosciences Inc.
Neurolixis Inc.
Taysha Gene Therapies Inc.
Ovid Therapeutics Inc.
Spinogenix Inc.
Epigen Biosciences Inc.
Confluence Pharmaceuticals Inc.
Actinogen Medical Limited
Sentinel Oncology Limited
Anavex Life Sciences Corp.
FRAXA Research Foundation Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
취약 X 증후군(FXS) 치료 시장 2029년 : 새로운 기회를 제공하는 국가
취약 X 증후군(FXS) 치료 시장 2029년 : 새로운 기회를 제공하는 부문
취약 X 증후군(FXS) 치료 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Fragile X Syndrome (FXS) treatment encompasses a combination of medical, therapeutic, and educational strategies aimed at managing symptoms and enhancing the quality of life for individuals affected by this genetic disorder, which leads to intellectual disabilities, behavioral challenges, and developmental delays. Common symptoms include developmental delays, difficulties in social interaction and communication, along with distinct physical features such as an elongated face and prominent ears. Treatment for FXS commonly involves pharmaceutical drugs such as antidepressants, antipsychotics, and stimulants to address behavioral concerns.
The primary treatment approaches for FXS include pharmacological interventions, psychotherapy, and educational and training programs. Pharmacological treatment focuses on using medications to manage symptoms such as anxiety, hyperactivity, and mood disorders, targeting specific neurological and behavioral challenges to improve patient well-being. These medications may be delivered orally, via injections, or through topical applications. Related conditions include Fragile X Syndrome, Fragile X Mental Retardation 1 (FMR1)-related primary ovarian insufficiency, Fragile X-linked Fragile E (XE) syndrome, Renpenning syndrome, and other associated disorders. Treatments are applied across all age groups-children, adults, and the elderly and are generally provided in hospitals, specialized clinics, and various healthcare facilities.
The fragile x syndrome (FXS) treatment market research report is one of a series of new reports from The Business Research Company that provides fragile x syndrome (FXS) treatment market statistics, including the fragile x syndrome (FXS) treatment industry global market size, regional shares, competitors with the fragile x syndrome (FXS) treatment market share, detailed fragile x syndrome (FXS) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the fragile x syndrome (FXS) treatment industry. This fragile x syndrome (FXS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The fragile X syndrome FXS treatment market size has grown strongly in recent years. It will grow from $1.92 billion in 2024 to $2.08 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to heightened awareness of Fragile X Syndrome, a rising prevalence of genetic disorders, increased adoption of early diagnosis and screening practices, expanded government funding for rare disease research, and growing demand for personalized treatment approaches.
The fragile X syndrome FXS treatment market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing demand for targeted therapies, a heightened focus on gene therapies, growing awareness of rare genetic disorders, greater adoption of telemedicine for consultations, and broader insurance coverage for rare disease treatments. Key trends during this period include technological progress in genetic testing, advancements in gene-editing therapies, increased investment in research and development, innovations in personalized treatment methods, and improvements in behavioral therapy approaches.
Government initiatives and funding for rare diseases are expected to drive the expansion of the fragile X syndrome (FXS) treatment market in the near future. Rare diseases are medical conditions that impact a small fraction of the population and are often chronic, progressive, and potentially life-threatening. The rise in the identification of rare diseases can be attributed to enhanced diagnostic capabilities advancements in genetic testing, imaging, and data analysis have significantly improved the accuracy of diagnosing conditions that were previously undetected or misdiagnosed. Fragile X syndrome (FXS) treatment highlights the significance of government funding by underlining the need for specialized therapies and early interventions, which help to raise awareness and channel resources toward expanded research and medical care. For instance, in February 2024, the UK Parliament's House of Commons Library reported a government commitment of £14 million ($17.3 million) to create a national rare disease research platform, featuring 11 research nodes and a central coordinating hub across the UK. Therefore, government investment in rare diseases is accelerating the growth of the FXS treatment market.
Key players in the fragile X syndrome (FXS) treatment market are prioritizing the development of innovative therapies, such as calcium-activated potassium (BK) channel activators, to address underlying neurological dysfunction and improve treatment outcomes. A BK channel activator enhances the function of potassium channels that control cell excitability and neurotransmitter release. For example, in January 2025, Spinogenix Inc., a US-based biotechnology company, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SPG601, a BK channel activator intended for FXS treatment. This designation accelerates clinical development and regulatory approval, bringing this novel therapeutic option designed to address synaptic dysfunction closer to patients. It also reflects the urgent need for effective FXS treatments and the potential of SPG601 to alleviate cognitive and behavioral symptoms by targeting key neurological mechanisms.
In August 2023, Harmony Biosciences Holdings Inc., a US-based commercial-stage pharmaceutical firm, acquired Zynerba Pharmaceuticals for approximately $60 million. This acquisition enables Harmony to diversify its therapeutic offerings and strengthen its pipeline by integrating Zynerba's lead candidate, Zygel a synthetic cannabidiol gel currently in Phase 3 trials for Fragile X syndrome and Phase 2 trials for 22q11.2 deletion syndrome. Zygel has received both orphan drug and FDA Fast Track designations for Fragile X syndrome. Zynerba Pharmaceuticals Inc. is a US-based biopharma company specializing in the development of transdermal cannabinoid treatments for FXS.
Major players in the fragile x syndrome (fxs) treatment market are F. Hoffmann-La Roche Ltd, Shionogi & Co. Ltd., Marinus Pharmaceuticals Inc., Healx Ltd, Neuren Pharmaceuticals Limited, Vincerx Pharma Inc., Fulcrum Therapeutics Inc., Neuronascent Inc., Autifony Therapeutics Limited, Quadrant Biosciences Inc., Neurolixis Inc., Taysha Gene Therapies Inc., Ovid Therapeutics Inc., Spinogenix Inc., Epigen Biosciences Inc., Confluence Pharmaceuticals Inc., Actinogen Medical Limited, Sentinel Oncology Limited, Anavex Life Sciences Corp., FRAXA Research Foundation Inc.
North America was the largest region in the fragile X syndrome FXS treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fragile x syndrome (FXS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the fragile x syndrome (FXS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The fragile x syndrome (FXS) treatment market consists of sales of genetic testing services, gene therapies, and behavioral intervention program. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Fragile X Syndrome (FXS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on fragile x syndrome (fxs) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for fragile x syndrome (fxs) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fragile x syndrome (fxs) treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment Type: Pharmacological Treatment; Psychotherapy; Education And Training
2) By Route of Administration: Oral; Injectable; Topical
3) By Related Disorder: Fragile X Syndrome; Fragile X Mental Retardation 1 (FMR1)-Related Primary Ovarian Insufficiency; Fragile X-linked Fragile E (XE) Syndrome; Renpenning Syndrome; Other Related Disorders
4) By Patient Age Group: Children; Adults; Elderly
5) By End-User: Hospitals; Specialty Clinics; Other End Users
2) By Psychotherapy: Cognitive Behavioral Therapy (CBT); Family Therapy; Social Skills Training; Occupational Therapy; Speech And Language Therapy; Applied Behavior Analysis (ABA)
3) By Education And Training: Special Education Programs; Individualized Education Programs (IEPs); Parent Training And Support; Behavioral Intervention Plans; Skill-Building Workshops; Inclusive Classroom Strategies
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Fragile X Syndrome (FXS) Treatment Market Characteristics
3. Fragile X Syndrome (FXS) Treatment Market Trends And Strategies
4. Fragile X Syndrome (FXS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Fragile X Syndrome (FXS) Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Fragile X Syndrome (FXS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Fragile X Syndrome (FXS) Treatment Market Growth Rate Analysis
5.4. Global Fragile X Syndrome (FXS) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Fragile X Syndrome (FXS) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Fragile X Syndrome (FXS) Treatment Total Addressable Market (TAM)
6. Fragile X Syndrome (FXS) Treatment Market Segmentation
6.1. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmacological Treatment
Psychotherapy
Education And Training
6.2. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Topical
6.3. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fragile X Syndrome
Fragile X Mental Retardation 1 (FMR1)-Related Primary Ovarian Insufficiency
Fragile X-linked Fragile E (XE) Syndrome
Renpenning Syndrome
Other Related Disorders
6.4. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Children
Adults
Elderly
6.5. Global Fragile X Syndrome (FXS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End Users
6.6. Global Fragile X Syndrome (FXS) Treatment Market, Sub-Segmentation Of Pharmacological Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.7. Global Fragile X Syndrome (FXS) Treatment Market, Sub-Segmentation Of Psychotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cognitive Behavioral Therapy (CBT)
Family Therapy
Social Skills Training
Occupational Therapy
Speech And Language Therapy
Applied Behavior Analysis (ABA)
6.8. Global Fragile X Syndrome (FXS) Treatment Market, Sub-Segmentation Of Education And Training, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Special Education Programs
Individualized Education Programs (IEPs)
Parent Training And Support
Behavioral Intervention Plans
Skill-Building Workshops
Inclusive Classroom Strategies
7. Fragile X Syndrome (FXS) Treatment Market Regional And Country Analysis
7.1. Global Fragile X Syndrome (FXS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Fragile X Syndrome (FXS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market
8.1. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Fragile X Syndrome (FXS) Treatment Market
9.1. China Fragile X Syndrome (FXS) Treatment Market Overview
9.2. China Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Fragile X Syndrome (FXS) Treatment Market
10.1. India Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Fragile X Syndrome (FXS) Treatment Market
11.1. Japan Fragile X Syndrome (FXS) Treatment Market Overview
11.2. Japan Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Fragile X Syndrome (FXS) Treatment Market
12.1. Australia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Fragile X Syndrome (FXS) Treatment Market
13.1. Indonesia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Fragile X Syndrome (FXS) Treatment Market
14.1. South Korea Fragile X Syndrome (FXS) Treatment Market Overview
14.2. South Korea Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Fragile X Syndrome (FXS) Treatment Market
15.1. Western Europe Fragile X Syndrome (FXS) Treatment Market Overview
15.2. Western Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Fragile X Syndrome (FXS) Treatment Market
16.1. UK Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Fragile X Syndrome (FXS) Treatment Market
17.1. Germany Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Fragile X Syndrome (FXS) Treatment Market
18.1. France Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Fragile X Syndrome (FXS) Treatment Market
19.1. Italy Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Fragile X Syndrome (FXS) Treatment Market
20.1. Spain Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Fragile X Syndrome (FXS) Treatment Market
21.1. Eastern Europe Fragile X Syndrome (FXS) Treatment Market Overview
21.2. Eastern Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Fragile X Syndrome (FXS) Treatment Market
22.1. Russia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Fragile X Syndrome (FXS) Treatment Market
23.1. North America Fragile X Syndrome (FXS) Treatment Market Overview
23.2. North America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Fragile X Syndrome (FXS) Treatment Market
24.1. USA Fragile X Syndrome (FXS) Treatment Market Overview
24.2. USA Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Fragile X Syndrome (FXS) Treatment Market
25.1. Canada Fragile X Syndrome (FXS) Treatment Market Overview
25.2. Canada Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Fragile X Syndrome (FXS) Treatment Market
26.1. South America Fragile X Syndrome (FXS) Treatment Market Overview
26.2. South America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Fragile X Syndrome (FXS) Treatment Market
27.1. Brazil Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Fragile X Syndrome (FXS) Treatment Market
28.1. Middle East Fragile X Syndrome (FXS) Treatment Market Overview
28.2. Middle East Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Fragile X Syndrome (FXS) Treatment Market
29.1. Africa Fragile X Syndrome (FXS) Treatment Market Overview
29.2. Africa Fragile X Syndrome (FXS) Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Fragile X Syndrome (FXS) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Fragile X Syndrome (FXS) Treatment Market, Segmentation By Related Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Fragile X Syndrome (FXS) Treatment Market Competitive Landscape And Company Profiles
30.1. Fragile X Syndrome (FXS) Treatment Market Competitive Landscape
30.2. Fragile X Syndrome (FXS) Treatment Market Company Profiles
30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Shionogi & Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Marinus Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Healx Ltd Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Neuren Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
31. Fragile X Syndrome (FXS) Treatment Market Other Major And Innovative Companies
31.1. Vincerx Pharma Inc.
31.2. Fulcrum Therapeutics Inc.
31.3. Neuronascent Inc.
31.4. Autifony Therapeutics Limited
31.5. Quadrant Biosciences Inc.
31.6. Neurolixis Inc.
31.7. Taysha Gene Therapies Inc.
31.8. Ovid Therapeutics Inc.
31.9. Spinogenix Inc.
31.10. Epigen Biosciences Inc.
31.11. Confluence Pharmaceuticals Inc.
31.12. Actinogen Medical Limited
31.13. Sentinel Oncology Limited
31.14. Anavex Life Sciences Corp.
31.15. FRAXA Research Foundation Inc.
32. Global Fragile X Syndrome (FXS) Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Fragile X Syndrome (FXS) Treatment Market
34. Recent Developments In The Fragile X Syndrome (FXS) Treatment Market
35. Fragile X Syndrome (FXS) Treatment Market High Potential Countries, Segments and Strategies
35.1 Fragile X Syndrome (FXS) Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Fragile X Syndrome (FXS) Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Fragile X Syndrome (FXS) Treatment Market In 2029 - Growth Strategies
